SK biopharmaceuticals

At a glance

SK biopharmaceuticals filed 64 disclosures in the last 12 months, including 9 contract, 5 insider, 4 earnings, 3 5% holder and 2 issuance. The most recent key filing was on Sep 23: Worth 9% of last year's revenue, over about 1 month.

Revenue for 2025 was ₩707B, up 29.1% on 2024. Operating margin was 28.9% against 17.6% a year earlier. Debt was 45% of equity at year end. The latest interim report (2026 H1) shows revenue of ₩475B and operating profit of ₩187B.

The 2025 annual report lists 272 employees with an average tenure of 6.3 years and average pay of ₩109M, #120 of 1,829 listed companies by average pay. Its 7 directors and auditors were paid ₩331M each on average. It paid no cash dividend for 2025. SK(주) and related parties held 64.00% at year end.

From the 2025 annual report

Staff: 272 (136 men, 136 women), of whom 23 on fixed-term contracts. Total pay for the year: ₩32.8B. Directors and auditors: 7, paid ₩2.3B in total.

No cash dividend was paid for 2025.

Largest shareholder

SK(주) holds 64.00%; with 6 related parties the group holds 64.00% of common shares at year end.

Individuals paid ₩500M or more

Auditor: 한영회계법인 · opinion: Unqualified.

Rankings: Operating margin #24 of 1,376

Source: 2025 annual business report (DART). How figures are combined

New contracts, last 12 months

3 new supply contracts worth 33% of the revenue stated in the filings.

Amended amounts replace the originals. Subsidiary contracts and terminations are excluded.

Financial summary